Participant :

Lab code :

METHOD DESCRIPTION

SCREENING ANALYSIS

(short description of the screening method / equipment)

**Sample preparation:**

**Sample amount:** ……. mL/mg of urine sample

**Hydrolysis:** yes [ ]  no [ ]  if yes: glucoronidase/sulfatase [ ]

 protease [ ]

 mineralic acid [ ]

 other ………………………..

**Clean-up:** liquid/liquid [ ]  solvent: ........................................... SPE [ ]  phase: ............. solvent: ...................

 QuECHERS [ ]

 other: ........................................................................

**Derivatisation:**  yes [ ]  if yes - reagent: ............................................

 no: [ ]

**Measurement method:** LC [ ]  column: .........................................................

temperature programme:...............................

 eluent: ...........................................................

 gradient:.........................................................

 .........................................................

 flow rate::......................................................

 column temperature:......................................

 injection volume:...........................................

 ELISA [ ]

 Biosensor [ ]

 Test-Kit [ ]

 other: ............................

**Detection method:** MS  [ ]  equipment: ........................................

 Ion trap: [ ]

 Triple quad: [ ]

 TOF / QTOF: [ ]

 Orbitrap: [ ]

 FLU [ ]

 DAD [ ]

 UV [ ]

 other: …………………………................................

**MS/MS conditions (diagnostic ions):**

|  |  |  |  |
| --- | --- | --- | --- |
| **Analyte** | **Precursor Ion** | **Product Ions** | **IS** |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
| **Internal Standards** |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |

**Source of Standards: ..……………………………………………………………………..**

 **………………………………………………………………………**

 **………………………………………………………………………**

 **………………………………………………………………………**

 **………………………………………………………………………**

 **………………………………………………………………………**

 **………………………………………………………………………**

**Calibration:** External calibration (solvent) [ ]

 single-level: [ ]

 multi-level: [ ]

 Matrix calibration [ ]

 single-level: [ ]

 multi-level: [ ]

 Calibration with IS [ ]

 Standard addition [ ]

**Additional remarks:** ………………………………………………………………………….

 ………………………………………………………………………..

 ………………………………………………………………………..

 ………………………………………………………………………..

 ………………………………………………………………………..

 ………………………………………………………………………..

**Reference (method):** ………………………………………………………………………….

Which analytes can be detected with this screening method? What is the CCβscreening for these analytes in this matrix?

|  |  |  |
| --- | --- | --- |
| **Analyte** | **Measurement and detection method** | **CCβscreening\* in egg (µg/kg)** |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |

**\*Please indicate the values for all individual substances.**

Remarks: *If data concerning the CCβ screening cannot be entered yet, please indicate the limit of quantification and limit of*

*determination or similar limits and the type of determination. Please mark entries correspondingly.*

***If several methods were used for the screening analysis, please copy pages1 to 6 and fill them in***

***separetely for each method.***

Participant :

Lab code :

RESULT FORM

SCREENING ANALYSIS

The screening results of the above-mentioned sample were positive for the following coccidiostats:

*(Please note that only one sample preparation per sample was required. If parallel analyses were performed, please enter* ***each individual result****,* ***do not enter means****!)*

***Sample code: ..................***

|  |  |  |
| --- | --- | --- |
| **Detected** **analytes** | **Nature of screening result****(please tick)** | **Concentration**  **(single values)** **(ng/mL urine)** |
| estimated | semi-quantitative | quantitative |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |

The presence of β-agonists in the above mentioned sample is not indicated by the screening results: [ ]

Remarks: .....................................................................................................................................

***Sample code: ................***

|  |  |  |
| --- | --- | --- |
| **Detected** **analytes** | **Nature of screening result****(please tick)** | **Concentration**  **(single values)** **(ng/mL urine)**estimated |
| estimated | semi-quantitative | quantitative |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |

The presence of β-agonists in the above mentioned sample is not indicated by the screening results: [ ]

Remarks: .....................................................................................................................................

***Sample code: ................***

|  |  |  |
| --- | --- | --- |
| **Detected** **analytes** | **Nature of screening result****(please tick)** | **Concentration**  **(single values)** **(ng/mL urine)**estimated |
| estimated | semi-quantitative | quantitative |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |

The presence of β-agonists in the above mentioned sample is not indicated by the screening results: [ ]

Remarks: .....................................................................................................................................

***Sample code: ..............***

|  |  |  |
| --- | --- | --- |
| **Detected** **analytes** | **Nature of screening result****(please tick)** | **Concentration**  **(single values)** **(ng/mL urine)**estimated |
| estimated | semi-quantitative | quantitative |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |

The presence of β-agonists in the above mentioned sample is not indicated by the screening results: [ ]

Remarks: .....................................................................................................................................

**How do you confirm a positive screening result?**

 **Method: …………………………………………………………**

 **Laboratory: …………………………………………………………**